Clinical Report: FDA approves dual-energy AFib ablation catheter
Overview
The FDA has approved Abbott's TactiFlex Duo Ablation Catheter for patients with atrial fibrillation.
Background
Atrial fibrillation (AFib) is a common arrhythmia that can lead to serious complications such as stroke and heart failure. The development of advanced ablation technologies, such as dual-energy catheters, is crucial for addressing challenging AFib cases.
Data Highlights
Favorable safety and effectiveness outcomes were reported in a study involving patients with paroxysmal AFib, presented at the European Society of Cardiology Congress 2026 and published in EP Europace.
Key Findings
- The TactiFlex Duo Ablation Catheter can deliver pulsed field ablation or radiofrequency energy individually or in combination.
- It integrates with Abbott’s EnSite X EP system, providing 3D heart mapping and real-time information during procedures.
- The catheter is designed for challenging cases of atrial fibrillation.
- FDA approval followed a CE Mark approval in Europe in 2026.
- Electrophysiology is rapidly evolving with new technologies improving AFib treatment safety and effectiveness.
Clinical Implications
The approval of the TactiFlex Duo catheter provides electrophysiologists with a new tool for managing complex AFib cases.
Conclusion
The FDA's approval of the TactiFlex Duo Ablation Catheter represents a notable advancement in the treatment of atrial fibrillation.
Related Resources & Content
- Abbott, Abbott News, 2026 -- Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
- MDSpire News, MDSpire News, 2026 -- FDA Approves Dual-Energy Catheter Ablation Platform
- MDSpire News, MDSpire News, 2026 -- Pulsed-Field Ablation System Approved by FDA for Patients With Paroxysmal Atrial Fibrillation
- HRS, HRS Releases Scientific Statement on Pulsed Field Ablation for Cardiac Arrhythmias, 2026
- reuters — FDA Approves New Heart Device for AF
- Clinical Research in Cardiology — Clinical Outcomes in Patients Exhibiting Dual Conduction Pathways in the Atrioventricular Node: Findings from a Multicenter Observational Study
- HRS Releases Scientific Statement on Pulsed Field Ablation for Cardiac Arrhythmias - HRS
- Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study - PubMed
- Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms - Sep 8, 2026
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
